Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects

Kim, Nam-Tae; Cho, Chang‐Keun; Kang, Pureum; Park, Hye-Jung; Lee, Yun Jeong; Bae, Jung‐Woo; Jang, Choon‐Gon; Lee, Seok‐Yong

doi:10.1007/s12272-021-01366-y

Cited by 16 publications

(3 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Randomized, double-blind, active-controlled Alogliptin therapy sustained blood sugar control equivalent to glipizide in T2DM patients without weight gain or hypoglycemia [43] 24 healthy Korean individuals Compared to CYP2C9*1/*1 wild-type people, faulty CYP2C9*3 and CYP2C9*13 alleles exhibited much increased plasma glipizide concentrations [44] 30 women with polycystic ovary syndrome (PCOS)…”

Section: Type Resultsmentioning

confidence: 99%

“…Glipizide pharmacokinetics were affected by the CYP2C9*3 and *13 alleles. Hence, glipizide plasma concentrations are much higher in people with the faulty CYP2C9*3 and *13 alleles than in those with the wild-type gene [43]. During this study, thirty women diagnosed with polycystic ovarian syndrome were given the medications glipizide and metformin (PCOS).…”

Section: Clinical Trialsmentioning

confidence: 99%

“…Alogliptin therapy sustained blood sugar control equivalent to glipizide in T2DM patients without weight gain or hypoglycemia 43…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Encyclopaedic Review of Glipizide Pre-clinical and Clinical Status

Mohammed,

Mahmood,

Shamim

et al. 2024

Drug Res (Stuttg)

View full text Add to dashboard Cite

Glipizide is an oral glucose-lowering medication that is beneficial for the treatment of type 2 diabetes. This study compiles exhaustively all accessible information on glipizide, from preclinical to clinical studies. Glipizide may be used in concert with TRAIL to treat cancer cells; in vitro studies have shown that it suppresses angiogenesis and vasculogenesis while shielding cells from glycation-induced damage. Anticonvulsant effects and modifications in the pharmacokinetics of other medications, such as Divalproex Sodium, were seen in glipizide in vivo experiments. Propranolol amplifies glipizide's hypoglycemic effect briefly in normal animals but consistently enhances it in diabetic ones. In the treatment of cancer and neurodegenerative poly(Q) illnesses, glipizide has demonstrated to offer potential therapeutic advantages. It is ineffective in preventing DENA-induced liver cancer and may cause DNA damage over time. The way glipizide interacts with genetic variants may increase the risk of hypoglycemia. Combining Syzygium cumini and ARBE to glipizide may enhance glycemic and lipid control in type 2 diabetes. Individuals with coronary artery disease who take glipizide or glyburide have an increased risk of death. The risk of muscular responses and acute pancreatitis is minimal when glipizide and dulaglutide are combined. In conclusion, glipizide has shown promising therapeutic efficacy across a variety of disorders.

show abstract

Section: Type Resultsmentioning

confidence: 99%

Section: Clinical Trialsmentioning

confidence: 99%